Abstract
BackgroundCurrent immunotherapy for patients with high-risk neuroblastoma involves the therapeutic antibody dinutuximab that targets GD2, a ganglioside expressed on the majority of neuroblastoma tumors. Opsonized tumor cells are killed through...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have